ClinicalTrials.gg
RecruitingNCT06483880Updated Feb 17, 2025

The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection

An interventional study of Albendazole and Placebo in Pulmonary Hydatid Cyst, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Ain Shams University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Feb 2024, registered Jun 2024).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Sex
All
01

Study summary

The aim of this study is to study the role of adjuvant Albendazole after pulmonary hydatid cyst resection versus placebo in reducing recurrence with a short- term follow-up of six months.

Read the detailed description

Hydatid disease, also referred to as cystic echinococcosis, is a major zoonotic disease with global distribution caused by the larval stage of the Echinococcus parasite, which belongs to the Taeniidae family and Echinococcus genus.

Cystic Echinococcosis is prevalent in several regions across the globe, including Mediterranean countries, southern America, Australia, eastern and northern Africa, as well as the Tibetan terrain of Asia.

Dogs and other members of the canid family serve as definitive hosts, as they harbor adult tapeworms within their intestinal tract and excrete parasite eggs in their feces. The intermediate hosts, which encompass a wide range of mammalian species including humans, can get accidentally infected through the ingestion of eggs via food or water that has been contaminated. Upon ingestion of tapeworm eggs found in the feces of dogs, the embryos are liberated from the eggs, traverse the intestinal mucosa, and disseminate to various organs via the bloodstream. The liver accounting for 60% to 70% of infections, and the lungs, comprising around 20% to 30% of infected cases, are the organs most frequently affected by infection.

Surgery is the gold standard treatment to get rid of a pulmonary hydatid cyst, though in some rare cases chemotherapy may be necessary. Despite claims that very small cysts can disappear on their own, surgery remains the gold standard for treating hydatid cysts. Re-surgery after recurrence is associated with increased operative morbidity and mortality. Surgical intervention may sometimes be required due to the development of complications in patients who receive only medical treatment.

Mebendazole was initially used for the therapeutic treatment of the hydatid cyst. Nevertheless, the drug's uptake from the gastrointestinal tract was poor, prompting its substitution with albendazole, which has better absorption. The drug's activity is enhanced by its metabolite, albendazole sulfoxide, which readily diffuses through the cyst membrane and accumulates in the cyst fluid. It has been shown that adjuvant albendazole treatment is effective in reducing recurrence postoperatively in liver hydatidosis.

The standard care in Ain Shams University Hospitals regarding prescription of albendazole after surgery is surgeon's preference. To the best of our knowledge, there was a gap of knowledge regarding the role of adjuvant Albendazole after pulmonary hydatid cyst resection. So, we will conduct this study.

02

Conditions studied

  • Pulmonary Hydatid Cyst
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients regardless of age with pulmonary hydatid disease requiring surgical resection.
  2. Patients achieving complete resection of pulmonary hydatid disease.
  3. Patients with no extra pulmonary hydatid disease.
  4. Patients who have received preoperative albendazole.

Exclusion criteria

Exclusion Criteria:

  1. Patients with extra pulmonary hydatid disease requiring treatment after pulmonary resection.
  2. Patients with incomplete resection of pulmonary hydatid disease.
  3. Patients with pulmonary hydatid disease not amenable for resection.
  4. Patients with to Albendazole.
  5. Patients with liver dysfunction.
  6. Patients refusing to be enrolled in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Albendazole arm

    The administration of albendazole therapy is recommended at a dosage of 15 mg/kg/day, given in two equally split doses per day. This is within two 15-day cycles following surgery.

    Drug: Albendazole

  • Placebo comparator
    Placebo arm

    Patients will receive the placebo, which will be in two equally split doses per day. This is within two 15-day cycles following surgery.

    Drug: Placebo

Interventions

  • Patients will receive albendazole therapy at the recommended dosage.

  • DrugPlacebo

    Patients will receive the placebo, which will be starch tablets in the same dosage of albendazole.

06

What researchers measure

Primary outcomes

  1. Recurrence of pulmonary hydatid disease

    Recurrence of pulmonary hydatid disease in six months in both groups, assessed by: 1. Chest X-ray radiography after the 2 weeks. 2. CT chest in six months and after one year or symptoms requiring CT chest at any timing.

    Time frame: six months

Secondary outcomes

  1. Liver function tests (AST and ALT) between both groups.

    AST and ALT will be measured in U/L before operation and after completing the two 15-day cycles of Albendazole or Placebo in either group. And after six months in both groups.

    Time frame: Six months

  2. Length of hospital stay between both groups.

    Time frame: Six months

  3. In hospital mortality between both groups.

    Time frame: Six months

  4. Financial cost between both groups.

    Time frame: Six months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Arif SH, Shams-Ul-Bari, Wani NA, Zargar SA, Wani MA, Tabassum R, Hussain Z, Baba AA, Lone RA. Albendazole as an adjuvant to the standard surgical management of hydatid cyst liver. Int J Surg. 2008 Dec;6(6):448-51. doi: 10.1016/j.ijsu.2008.08.003. Epub 2008 Aug 16. PubMed 18819855 ↗
  • Aydin Y, Ulas AB, Ince I, Kalin A, Can FK, Gundogdu B, Kasali K, Kerget B, Ogul Y, Eroglu A. Evaluation of albendazole efficiency and complications in patients with pulmonary hydatid cyst. Interact Cardiovasc Thorac Surg. 2022 Jan 18;34(2):245-249. doi: 10.1093/icvts/ivab259. PubMed 34587626 ↗
  • Dehkordi AB, Sanei B, Yousefi M, Sharafi SM, Safarnezhad F, Jafari R, Darani HY. Albendazole and Treatment of Hydatid Cyst: Review of the Literature. Infect Disord Drug Targets. 2019;19(2):101-104. doi: 10.2174/1871526518666180629134511. PubMed 29956639 ↗
  • Fattahi Masoom SH, Lari SM, Fattahi AS, Ahmadnia N, Rajabi M, NaderiKalat M. Albendazole therapy in human lung and liver hydatid cysts: A 13-year experience. Clin Respir J. 2018 Mar;12(3):1076-1083. doi: 10.1111/crj.12630. Epub 2017 Apr 20. PubMed 28319358 ↗
  • Rawat S, Kumar R, Raja J, Singh RS, Thingnam SKS. Pulmonary hydatid cyst: Review of literature. J Family Med Prim Care. 2019 Sep 30;8(9):2774-2778. doi: 10.4103/jfmpc.jfmpc_624_19. eCollection 2019 Sep. PubMed 31681642 ↗
  • Sarkar M, Pathania R, Jhobta A, Thakur BR, Chopra R. Cystic pulmonary hydatidosis. Lung India. 2016 Mar-Apr;33(2):179-91. doi: 10.4103/0970-2113.177449. PubMed 27051107 ↗
  • Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother. 1993 Aug;37(8):1679-84. doi: 10.1128/AAC.37.8.1679. PubMed 8215283 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Jun 2025, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2024
First posted
Jul 3, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jul 1, 2025
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06483880
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Feb 1, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Feb 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albendazole

Start the discussion